Biofrontera Inc AI10
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AI10 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €0.92
- Day Range
- €0.98–1.05
- 52-Week Range
- €0.63–11.38
- Bid/Ask
- €0.98 / €1.05
- Market Cap
- €5.34 Mil
- Volume/Avg
- 75 / 0
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 85
- Website
- https://www.biofrontera-us.com
Valuation
|
Metric
|
AI10
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.05 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AI10
|
|---|---|
Quick Ratio | 0.54 |
Current Ratio | 1.44 |
Interest Coverage | −11.01 |
Quick Ratio
AI10
Profitability
|
Metric
|
AI10
|
|---|---|
Return on Assets (Normalized) | −69.86% |
Return on Equity (Normalized) | −475.01% |
Return on Invested Capital (Normalized) | −273.44% |
Return on Assets
AI10
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Zsvbynpl | Rbfxpb | $80.3 Bil | |||
| Zoetis Inc Class A
ZTS
| Bqqwwwbs | Plvk | $77.8 Bil | |||
| Haleon PLC ADR
HLN
| Kvtvpvng | Bwnw | $37.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Yjjwqvd | Drtzh | $12.1 Bil | |||
| Viatris Inc
VTRS
| Xktdxqd | Dgvdx | $12.1 Bil | |||
| Catalent Inc
CTLT
| Trwrvmndl | Ztrcztm | $10.0 Bil | |||
| Perrigo Co PLC
PRGO
| Nlwpgvfkt | Qfx | $3.7 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Pnlqhjtl | Dmbjk | $3.2 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Clrdxcn | Nhck | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Xchkfctsqh | Xnw | $2.7 Bil |